Wave Life Sciences Ltd
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −8.32%.
Did WVE Beat Earnings? Q4 2025 Results
Wave Life Sciences posted a sharply weaker Q4 2025, with revenue collapsing to $17.24 million from $83.75 million a year earlier as collaboration payments from GSK fell dramatically, swinging the company to a net loss of $53.18 million compared to net income of $29.25 million in the prior-year period. EPS came in at -$0.30 for the quarter, reflecting the steep drop in partnership revenue alongside rising R&D expenditures of $52.81 million as Wave pressed forward aggressively across its clinical pipeline. Yet the headline losses obscure a company in deliberate growth mode, with management pointing to a substantially fortified cash position of $602.07 million, nearly double the $302.08 million held a year prior, providing a runway it expects to extend into Q3 2028. The most compelling part of the story sits in the pipeline, where WVE-007, its GalNAc-siRNA obesity candidate, demonstrated fat loss comparable to GLP-1 therapies while preserving muscle mass, and WVE-006 is now pursuing an accelerated approval pathway for alpha-1 antitrypsin deficiency, with a late-breaking oral presentation slot secured at a major lung conference in May 2026.
- Revenue decline driven by lower GSK collaboration milestone and research funding recognition versus prior year
- Cash position nearly doubled year-over-year due to financing proceeds and GSK milestone payments
- R&D expense increases reflect advancement of obesity (WVE-007), AATD (WVE-006), and PNPLA3 (WVE-008) programs
“We entered 2026 focused on executing in two priority areas: accelerating development of WVE-007, our INHBE GalNAc-siRNA for obesity, and rapidly advancing our RNA editing portfolio, which includes WVE-006 for AATD and WVE-008 for PNPLA3 liver disease. WVE-007 is enabled by our leading RNAi capabilities supported by a differentiated and proprietary SpiNA design, and has the potential to be a transformative treatment approach for obesity. Our interim INLIGHT clinical data from the lowest therapeutic single-dose cohort demonstrated fat loss on par with GLP-1, favorable safety and tolerability, as well as the potential for once or twice a year dosing.”
Wave Life Sciences CEO, on the earnings call
Forward Guidance & Outlook
Wave expects its cash and cash equivalents of $602.1 million to fund operations into Q3 2028, excluding potential future GSK collaboration milestones. Key upcoming catalysts include: INLIGHT clinical data update (6-month 240 mg and 3-month 400 mg) in Q1 2026; Phase 2a multidose initiation for WVE-007 in H1 2026; new WVE-007 trials as an incretin add-on and post-incretin maintenance in 2026; WVE-006 RestorAATion-2 400 mg multidose data in Q1 2026 and 600 mg data throughout 2026; regulatory feedback on accelerated approval pathway for WVE-006 expected mid-2026; CTA filing for WVE-008 in 2026; and NDA filing for WVE-N531 for accelerated approval in 2026. The company anticipates continued milestone payments from GSK in 2026 and beyond.
WVE YoY Financials
Figures from SEC filings and company reports. Not investment advice.